Literature DB >> 6339045

Cellular uptake and inhibition of DNA synthesis by dihydroxyanthraquinone and two analogues.

A Nishio, E M Uyeki.   

Abstract

Three analogues of aminoalkylamino-substituted anthraquinone derivatives, namely, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthracenedione (DHAQ), 1-hydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthracenedione (HAQ), and 1,4-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthracenedione (AQ), were chosen with respect to the number of hydroxyl groups on the aromatic ring. DHAQ showed about 100 times more potent antiproliferative activity on cultured mouse L-cells than did AQ; HAW showed intermediate activity. This antiproliferative activity was correlated with their inhibitory effect on DNA synthesis in culture. When their inhibitory effect on DNA synthesis was conducted in a permeabilized L-cell assay, all compounds were inhibitory; the order of potency was DHAQ greater than HAQ greater than AQ. The same order of potency was also observed in calf thymus DNA and Escherichia coli DNA polymerase I system. Their inhibitory effect in the latter system was correlated with the drug:DNA molar ratio, and not with drug:enzyme ratio. Comparative uptake of the drugs by intact L-cells showed the highest uptake of DHAQ followed by those of HAQ and AQ. The large differences in their uptake by intact cells became minimal when cells were rendered permeable to exogenous materials or when nuclei were used. Hence, these studies revealed that the hydroxyl group on the aromatic ring of the compounds influenced their biological activity not only by potentiating drug-target interaction but also by drug uptake into cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339045

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  Development of mitoxantrone.

Authors:  R J White; F E Durr
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Condensation of nucleic acids by intercalating aromatic cations.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

6.  Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.

Authors:  Zahra Hajihassan; Azra Rabbani-Chadegani
Journal:  J Biomed Sci       Date:  2009-03-11       Impact factor: 8.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.